Ｃ．ディフィシル治療方法及び組成物

Japanese Patent JP7397071

B2

Disclosed herein are compositions and methods for preventing, ameliorating, or treating Clostridium difficile infections and/or reducing the severity of one or more risk factors, signs, or symptoms associated with C. difficile infections. In particular, the technology of the present disclosure relates to methods for administering an effective amount of a composition comprising strains of Bacillus amyloliquefaciens bacteria identified as ART24, ART4, and ART12, to a subject suffering from or at risk for C. difficile infections.

Farquhar Ronald
murphy christopher kay
hill colin
ross paul
rare mary
O'Donnell Michelle
healy brian
Chesnel Laurent

JP2021518039A

December 12, 2023

June 06, 2019

Click for automatic bibliography generation  

Altugen Therapeutics Limited

C12N1/20; A23K10/16; A23K50/80; A61K35/742; A61K38/14; A61K39/395; A61K45/00; A61K47/18; A61K47/22; A61K47/26; A61K47/36; A61P1/04; A61P1/06; A61P1/08; A61P1/12; A61P1/14; A61P31/04; A61P43/00

JP2009519238A

US20170224745
US20150257400
WO2013153159A1
WO2016118864A1
KR1020160141267A
US20150147303
CN104974950A

Geeraerts, S. et al.,Bacillus amyloliquefaciens as prophylactic treatment for Clostridium difficile-associated disease in a mouse model,Journal of gastroenterology and hepatology,30(8),2015年,p.1275-1280
Lee, J. Y. et al.,Antimicrobial activity of Bacillus amyloliquefaciens EMD17 isolated from Cheonggukjang and potential use as a starter for fermented soy foods,Food science and biotechnology,25(2),2016年,p.525-532

Shinichiro Tanaka
▲吉▼田 和彦
Hiroyuki Suda
Kazuo Yamazaki
Satsuki Ichikawa
Hironobu Hattori
Toshio Takizawa

Previous Patent: Methods and intermediates for the production of fluensulfone

Next Patent: 2,6-dimethyl-N-((pyridin-4-yl)methyl)imidazo[1,2-b]pyridazin-8-amine and 2,5-dimethyl-N-[(pyridine -...